Melanoma is the most aggressive form of skin cancer. If metastasis occurs, currently only about 10% of patients with the disease respond to standard treatment. This situation can be improved if patients at risk of metastasis are identified early, and if patients in which metastasis has already occurred undergo targeted treatment. In this project we describe the generation of new types of antibodies that can identify metastasis-specific antigens in a targeted manner, and which are being tested for suitability for diagnosis. The strength of our approach lies in the combined use of completed preclinical studies, established cell culture methods and in vivo models, as well as the antibody production expertise of Sciotec Diagnostic Technologies GmbH.
The Project under the consortial leadership of the Medical University of Vienna was funded by the Austrian Research Promotion Agency under the BRIDGE programme.